Danish Commercial Services Stock News

Danske Bank shareholders approved all Board proposals at the annual general meeting, including major changes to the Board and capital structure. Martin Blessing was elected Chairman of the Board, marking a leadership change at CPSE:DANSKE. Shareholders backed a reduction in share capital and renewed capital authorisations that reshape the bank’s capital framework. Danske Bank, trading at DKK318.1, has seen a 44.3% return over the past year and a gain over five years of 262.3%. These moves...

AL Sydbank (CPSE:ALSYDB) has come into focus after recent share price pressure, including a 1 day return of 1.1% and an almost 10% decline over the past 3 months, prompting closer attention from investors. See our latest analysis for AL Sydbank. With the share price at DKK505.0, recent momentum has been soft, with a 30 day share price return of a 5.5% decline and a 90 day share price return of a 9.9% decline, set against a 1 year total shareholder return of 20% and a very large 5 year total...

Investors may be wondering whether Novo Nordisk’s current share price reflects its true worth, or if the recent weakness is creating a potential value opportunity. The stock last closed at DKK 240.30, with returns of 1.0% over 7 days, a 1.4% decline over 30 days, a 27.2% decline year to date, and a 48.6% decline over 1 year, while the 5-year return stands at 20.2%. These moves sit against a backdrop of ongoing attention on Novo Nordisk’s role in pharmaceuticals and biotech, including...

SP Group (CPSE:SPG) has wrapped up FY 2025 with fourth quarter revenue of DKK 826.4 million and basic EPS of DKK 7.40, alongside trailing twelve month revenue of DKK 2.95 billion and EPS of DKK 22.21 that reflect a 1.6% earnings increase over the past year. Over recent periods the company has seen quarterly revenue range from DKK 654.8 million to DKK 826.4 million, with basic EPS moving between DKK 4.12 and DKK 7.40. The trailing net profit margin has edged to 9% from 8.9% a year earlier,...

Rockwool (CPSE:ROCK B) has proposed at its upcoming April 15, 2026 AGM to cancel 4,346,560 repurchased class B shares, cutting nominal share capital and amending its Articles of Association. See our latest analysis for Rockwool. That capital reduction proposal comes after a weak stretch for the share price, with a 1 month share price return of a 20.19% decline and a 1 year total shareholder return of a 41.48% decline. This suggests momentum has been soft, even though the 3 year total...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

Zealand Pharma (CPSE:ZEAL) is setting up a major U.S. research hub in Cambridge, Massachusetts, focused on AI-driven drug discovery and automation. The new site will support work on hybrid therapies, including antibody peptide conjugates and siRNAs, alongside the company’s peptide heritage. The expansion is intended to plug Zealand Pharma directly into the Boston life sciences cluster, with implications for scientific capabilities and hiring. For investors tracking Zealand Pharma at a share...

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...

FLSmidth (CPSE:FLS) has drawn fresh attention after announcing a joint venture with local industrial group Texnopark in Uzbekistan, aimed at building a modular service centre for mining customers across Central Asia. See our latest analysis for FLSmidth. While the new Uzbekistan joint venture is grabbing attention, FLSmidth’s 1-day share price return of 3.87% comes after a softer 30-day share price return of 12.49%. This is set against a 1-year total shareholder return of 35.21% and a 5-year...

Why Novozymes’ latest AGM matters for shareholders Novozymes (CPSE:NSIS B) has just wrapped up its Annual General Meeting, where shareholders approved the audited 2025 report and backed an ordinary dividend, putting capital returns and balance sheet choices in focus. See our latest analysis for Novozymes. Despite the AGM’s focus on dividends and capital structure, the share price return has been weaker recently, with a 30 day share price return of 9.66% and a year to date share price return...

Bylaw changes and capital structure moves grab investor attention Embla Medical hf (CPSE:EMBLA) has drawn fresh interest after its 2026 Annual General Meeting approved share capital reductions, renewed board authorizations for future capital increases, and set out conditions for new share buyback and employee option programs. See our latest analysis for Embla Medical hf. Despite the AGM activity around buybacks and share capital, Embla Medical hf's share price has eased in recent months, with...

Bavarian Nordic A/S recently reported full-year 2025 results, with sales rising to DKK 6,243.96 million and net income reaching DKK 1,375.38 million, alongside higher earnings per share from continuing operations. A day earlier, the company expanded its partnership with Serum Institute of India to transfer chikungunya vaccine manufacturing and explore further co-development, potentially broadening access in low- and middle-income countries. Next, we’ll assess how the chikungunya tech...

Ørsted (CPSE:ORSTED) has proposed the election of three new board members at its annual general meeting scheduled for April 2026. The nominees are Karen Boesen, Karl Johnny Hersvik, and Samuel Leupold, each bringing experience in energy and renewables. Two current board members are not seeking re election, which would reshape the composition of Ørsted's board if the proposals are approved. For shareholders, these board changes come with Ørsted's share price at DKK144.0 and a mixed return...

Why Coloplast’s CEO transition is in focus Coloplast (CPSE:COLO B) is back on investors’ radar after the board appointed Gavin Wood as President and CEO, effective 1 May 2026, following a year under interim chief Lars Rasmussen. Wood arrives from senior roles at Johnson & Johnson MedTech EMEA and previous leadership positions at Mölnlycke and Ethicon, raising questions about how his background could shape Coloplast’s future direction and its healthcare portfolio. See our latest analysis for...

Why Zealand Pharma stock is in focus after new obesity trial data Zealand Pharma (CPSE:ZEAL) has moved into the spotlight after announcing that its investigational obesity therapy petrelintide met the primary endpoint in a large Phase 2 trial, showing statistically significant weight loss versus placebo. See our latest analysis for Zealand Pharma. The positive petrelintide data arrives after a difficult period for Zealand Pharma shareholders. A 30 day share price return of 29.15% and a 90 day...

Københavns Lufthavne (CPSE:KBHL) has wrapped up FY 2025 with Q4 revenue of DKK 1,368 million and basic EPS of DKK 32.95, while trailing twelve month figures sit at DKK 5.5 billion in revenue and EPS of DKK 158.00, reflecting earnings growth of 19.6% over the period. The company has seen quarterly revenue move from DKK 1,245 million and EPS of DKK 24.98 in Q4 2024 to DKK 1,368 million and EPS of DKK 32.95 in Q4 2025, with margins stepping up from 20% to 22%. This puts profitability at the...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...

If you are wondering whether GN Store Nord's current share price reflects its true worth, you are not alone. This article is built to help you make sense of what the market is pricing in. GN Store Nord shares last closed at DKK 87.08, with returns of 6.2% decline over 7 days, 11.8% decline over 30 days, 20.8% decline year to date, 26.3% decline over 1 year, 39.0% decline over 3 years and 81.8% decline over 5 years. These moves may have shifted how investors think about both risk and...

Wondering if A.P. Møller - Mærsk is priced for its future or its past? This article walks you through what the current share price might be telling you about value. The stock closed at DKK 16,230, with returns of 6.6% over 30 days, 10.5% year to date and 46.1% over 1 year, so recent moves may have changed how you think about both upside and risk. Recent news has focused on Maersk's position in global container shipping and investor interest in how trade flows, freight demand and supply chain...

Scandinavian Tobacco Group (CPSE:STG) has drawn fresh attention after reporting full year 2025 results with lower sales and net income, issuing 2026 guidance, and proposing a reduced DKK 4.50 dividend per share. See our latest analysis for Scandinavian Tobacco Group. The latest earnings release and reduced dividend appear to have weighed on sentiment, with a 30 day share price return showing a decline of 32.61% and a year to date share price return showing a decline of 29.47%, while the 1...

If you are wondering whether Vestas Wind Systems is still priced attractively after a strong run, this article walks through how its current share price stacks up against different valuation checks. The stock trades at DKK159.70 after a 54.1% return over the past year, even though the 7 day, 30 day and year to date returns of 0.2% decline, 2.1% decline and 10.6% decline show that the ride has not been smooth. Recent coverage has focused on Vestas as a key player in global wind power build...

Investors may be wondering if Coloplast at around kr439.80 is starting to look interesting again, or if the current price still feels rich compared to its fundamentals. The share price has recorded a 4.7% decline over the last 7 days, a 10.6% decline over 30 days, an 18.0% decline year to date and a 37.1% decline over 1 year, while the 3 year and 5 year returns sit at declines of 41.9% and 45.6% respectively. These moves come as investors reassess the company against peers in the healthcare...

Bavarian Nordic (CPSE:BAVA) has wrapped up FY 2025 with Q4 revenue of DKK 1.5b and a basic EPS loss of DKK 4.13, capping a year in which trailing twelve month revenue came in at DKK 6.2b and basic EPS at DKK 17.6. Over the past few quarters, the company has seen revenue move from DKK 1.3b in Q1 2025 to DKK 1.8b in Q3 2025 before landing at DKK 1.5b in Q4, while quarterly basic EPS ranged from DKK 2.7 in Q1 and DKK 13.7 in Q3 to a loss in Q4. With trailing net profit margin at 22% compared to...